First Russian experience of pazopanib in the treatment of soft tissue sarcomas
Abstract
Sarcomas include soft tissue to tumors with high vascularization where angiogenesis plays an important role in their development and metastasis. most soft tissue sarcomas have a complex genetic profile with multiple mutations or aberrations, which make it difficult for the treatment with kinase inhibitors. Pazopanib – multityrosine kinase inhibitor of angiogenesis, targeted to receptors VEGFR-1, -2 and -3, and receptor and PDGFR-A and -B, c-Kit, which can provide long-term stabilization and objective responses in sarcomas.
Objective. Aim of the study was to evaluate the efficacy and safety of pazopanib in treatment of patients with soft tissue sarcomas.
Materials and Methods. 42 patients with metastatic soft tissue sarcomas in age from 19 till 78 years old after one or more lines of chemotherapy were enrolled in the study. Pazopanib was used in a dose of 800 mg Po daily.
Results. Efficacy of pazopanib was evaluated in 40 patients: CR – none, PR – in 1 patient (2.5%), SD – in 30 patients (75%), PD – in 9 patients (22.5%). Thus, control of tumor growth (complete remission, partial remission, stabilization) was achieved in 77.5%. The median time to progression was 8.3 months. The median overall survival has not been reached. Toxicity was mild and durable and almost the same as were reported in previous worldwide studies.
Conclusions. Based on the data obtained in this study pazopanib can be used as the second or more line of therapy. In some clinical cases efficacy of pazopanib was reported in patients with rare chemoresistant subtypes of STS.
About the Authors
A. A. Fedenko
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
A. A. Konev
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
B. U. Bokhyan
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
V. A. Gorbunova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. Давыдов М.И., Аксель Е.М. Смертность населения России и стран СНГ от злокачественных новообразований в 2008 г. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011 (3s).
2. Blay J.Y., van Glabbeke M., Verweij J. et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur. J. Cancer. 2003, v. 39, p. 64-69.
3. Kasper B., Hohenberger P. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. Future Oncol. 2011, v. 7, p. 1373-1383.
4. Dirix L.Y., Vermeulen P., De Wever I., Van Oosterom A.T. Soft tissue sarcoma in adults. Curr. Opin. Oncol. 1997, v. 9, p. 348-359.
5. Pakosi E., Goussia A.C., Tsekerisi G. et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res. 2005, v. 25, p. 3591-3596.
6. DuBois S., Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007, v. 109 (5), p. 813-819.
7. Hayes A.J., Mostyn-Jones A., Koban M.U. et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Brit. J. Surg. 2004, v. 91, p. 242-247.
8. Kilvaer T.K., Valkov A., Sorbye S. et al. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS ONE. 2010, v. 5 (12), E15368.
9. Sleijfer S., Ray-Coquard I., Papai Z. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J. Clin. Oncol. 2009, v. 27 (19), p. 3126-3132.
10. Casali P.G., Blay J.Y. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, v. 21 (suppl. 5), p. V198-V203.
11. Potti A., Ganti A.K., Tendulkar K. et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J. Cancer Res. Clin. Oncol. 2004, v. 130, p. 52-56.
12. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res. 2007, v. 13, p. 1098-1106.
13. Harris P.A., Boloor A., Cheung M. et al. Discovery of 5-[[4-[(2,3-Dimethyl- 2H-indazol-6-yl)methylamino]-2 pyrimidinyl] amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 2008, v. 51, p. 4632-4640.
14. Hurwitz H.I., Dowlati A., Saini S. et al. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin. Cancer Res. 2009, v. 15, p. 4220-4227.
15. Van der Graaf W.T.A., BlayJ.Y., ChawlaS.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2012, v. 379, p. 1879-1886.
16. Bramwell V. Pazopanib and the treatment palette for soft-tissue sarcoma. Lancet. 2012, v. 379, p. 1854-1856. Commentary on PALETTE study [PubMed: 22595798].
17. Ray-Coquard I., ThomasD. Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. Nat. Rev. Clin. Oncol. 2012, v. 9, p. 431-432. Commentary on PALETTE study. [PubMed: 22751280].
18. Ong P., Greulich S., Schumm J. et al. Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging. Circulation. 2012, v. 126, p. 279-281.
19. Keir S., Morton C., Wu J. et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. 2012, v. 59, p. 586-588. This is initial preclinical evidence of activity of pazopanib in childhood sarcomas [PubMed: 22190407].
20. D’Adamo D.R., Anderson S.E., Albritton K. et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005, v. 23, p. 7135-7142.
Review
For citations:
Fedenko A.A., Konev A.A., Bokhyan B.U., Gorbunova V.A. First Russian experience of pazopanib in the treatment of soft tissue sarcomas. Bone and soft tissue sarcomas, tumors of the skin. 2014;(3-4):44-51. (In Russ.)
Views:
2183
Email this article 
